Hypokalemia, hypocalcemia, hypomagnesemia, and an electrolyte disturbance resembling Bartter's syndrome have been reported to occur in patients with capreomycin toxicity. The subcutaneous median lethal dose (LD50) in mice was 514 mg/kg.
Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Capreomycin. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Capreomycin. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Capreomycin. |
| Cisatracurium | Capreomycin may increase the neuromuscular blocking activities of Cisatracurium. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Capreomycin. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Capreomycin. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Capreomycin. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Capreomycin. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Capreomycin. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Capreomycin. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Capreomycin. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Capreomycin. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Capreomycin. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Capreomycin. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Capreomycin. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Capreomycin. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Capreomycin. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Capreomycin. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Capreomycin. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Capreomycin. |
| Carboplatin | The risk or severity of ototoxicity and nephrotoxicity can be increased when Capreomycin is combined with Carboplatin. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Capreomycin is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Capreomycin. |
| Tenofovir disoproxil | Capreomycin may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Capreomycin. |
| Tenofovir | Capreomycin may increase the nephrotoxic activities of Tenofovir. |
| Zoledronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Zoledronic acid. |
| Alendronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Alendronic acid. |
| Ibandronate | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Ibandronate. |
| Clodronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Clodronic acid. |
| Risedronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Risedronic acid. |
| Etidronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Etidronic acid. |
| Incadronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Incadronic acid. |
| Taxifolin | The risk or severity of nephrotoxicity can be increased when Taxifolin is combined with Capreomycin. |
| Licofelone | The risk or severity of nephrotoxicity can be increased when Licofelone is combined with Capreomycin. |
| Polmacoxib | The risk or severity of nephrotoxicity can be increased when Polmacoxib is combined with Capreomycin. |
| Ebselen | The risk or severity of nephrotoxicity can be increased when Ebselen is combined with Capreomycin. |
| Flurbiprofen axetil | The risk or severity of nephrotoxicity can be increased when Flurbiprofen axetil is combined with Capreomycin. |
| Acetyldigitoxin | The risk or severity of adverse effects can be increased when Capreomycin is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of adverse effects can be increased when Capreomycin is combined with Deslanoside. |
| Ouabain | The risk or severity of adverse effects can be increased when Capreomycin is combined with Ouabain. |
| Digitoxin | The risk or severity of adverse effects can be increased when Capreomycin is combined with Digitoxin. |
| Oleandrin | The risk or severity of adverse effects can be increased when Capreomycin is combined with Oleandrin. |
| Cymarin | The risk or severity of adverse effects can be increased when Capreomycin is combined with Cymarin. |
| Proscillaridin | The risk or severity of adverse effects can be increased when Capreomycin is combined with Proscillaridin. |
| Metildigoxin | The risk or severity of adverse effects can be increased when Capreomycin is combined with Metildigoxin. |
| Lanatoside C | The risk or severity of adverse effects can be increased when Capreomycin is combined with Lanatoside C. |
| Gitoformate | The risk or severity of adverse effects can be increased when Capreomycin is combined with Gitoformate. |
| Acetyldigoxin | The risk or severity of adverse effects can be increased when Capreomycin is combined with Acetyldigoxin. |
| Peruvoside | The risk or severity of adverse effects can be increased when Capreomycin is combined with Peruvoside. |
| Torasemide | The serum concentration of Capreomycin can be increased when it is combined with Torasemide. |
| Bumetanide | The serum concentration of Capreomycin can be increased when it is combined with Bumetanide. |
| Etacrynic acid | The serum concentration of Capreomycin can be increased when it is combined with Etacrynic acid. |
| Piretanide | The serum concentration of Capreomycin can be increased when it is combined with Piretanide. |
| Azosemide | The serum concentration of Capreomycin can be increased when it is combined with Azosemide. |
| Tripamide | The serum concentration of Capreomycin can be increased when it is combined with Tripamide. |
| Flucloxacillin | The serum concentration of Capreomycin can be decreased when it is combined with Flucloxacillin. |
| Phenoxymethylpenicillin | The serum concentration of Capreomycin can be decreased when it is combined with Phenoxymethylpenicillin. |
| Dicloxacillin | The serum concentration of Capreomycin can be decreased when it is combined with Dicloxacillin. |
| Carbenicillin | The serum concentration of Capreomycin can be decreased when it is combined with Carbenicillin. |
| Nafcillin | The serum concentration of Capreomycin can be decreased when it is combined with Nafcillin. |
| Hetacillin | The serum concentration of Capreomycin can be decreased when it is combined with Hetacillin. |
| Benzylpenicilloyl polylysine | The serum concentration of Capreomycin can be decreased when it is combined with Benzylpenicilloyl polylysine. |
| Mezlocillin | The serum concentration of Capreomycin can be decreased when it is combined with Mezlocillin. |
| Cyclacillin | The serum concentration of Capreomycin can be decreased when it is combined with Cyclacillin. |
| Benzylpenicillin | The serum concentration of Capreomycin can be decreased when it is combined with Benzylpenicillin. |
| Azlocillin | The serum concentration of Capreomycin can be decreased when it is combined with Azlocillin. |
| Cloxacillin | The serum concentration of Capreomycin can be decreased when it is combined with Cloxacillin. |
| Amdinocillin | The serum concentration of Capreomycin can be decreased when it is combined with Amdinocillin. |
| Bacampicillin | The serum concentration of Capreomycin can be decreased when it is combined with Bacampicillin. |
| Meticillin | The serum concentration of Capreomycin can be decreased when it is combined with Meticillin. |
| Pivampicillin | The serum concentration of Capreomycin can be decreased when it is combined with Pivampicillin. |
| Pivmecillinam | The serum concentration of Capreomycin can be decreased when it is combined with Pivmecillinam. |
| Ticarcillin | The serum concentration of Capreomycin can be decreased when it is combined with Ticarcillin. |
| Azidocillin | The serum concentration of Capreomycin can be decreased when it is combined with Azidocillin. |
| Carindacillin | The serum concentration of Capreomycin can be decreased when it is combined with Carindacillin. |
| Sultamicillin | The serum concentration of Capreomycin can be decreased when it is combined with Sultamicillin. |
| Temocillin | The serum concentration of Capreomycin can be decreased when it is combined with Temocillin. |
| Epicillin | The serum concentration of Capreomycin can be decreased when it is combined with Epicillin. |
| Pheneticillin | The serum concentration of Capreomycin can be decreased when it is combined with Pheneticillin. |
| Carfecillin | The serum concentration of Capreomycin can be decreased when it is combined with Carfecillin. |
| Propicillin | The serum concentration of Capreomycin can be decreased when it is combined with Propicillin. |
| Clometocillin | The serum concentration of Capreomycin can be decreased when it is combined with Clometocillin. |
| Sulbenicillin | The serum concentration of Capreomycin can be decreased when it is combined with Sulbenicillin. |
| Penamecillin | The serum concentration of Capreomycin can be decreased when it is combined with Penamecillin. |
| Talampicillin | The serum concentration of Capreomycin can be decreased when it is combined with Talampicillin. |
| Aspoxicillin | The serum concentration of Capreomycin can be decreased when it is combined with Aspoxicillin. |
| Metampicillin | The serum concentration of Capreomycin can be decreased when it is combined with Metampicillin. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Capreomycin. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Capreomycin. |
| Lymecycline | The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Capreomycin. |
| Clomocycline | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Clomocycline. |
| Quinine | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Quinine. |
| Tigecycline | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Tigecycline. |
| Oxytetracycline | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Oxytetracycline. |
| Demeclocycline | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Demeclocycline. |
| Magnesium sulfate | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium sulfate. |
| Metacycline | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Metacycline. |
| Minocycline | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Minocycline. |
| Clindamycin | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Clindamycin. |